1887

Abstract

SUMMARY

Epstein—Barr (EB) virus membrane antigen (MA) glycoprotein (gp340) purified by a molecular weight-based technique has been subjected to biochemical analysis. Following treatment with glycosidases or tunicamycin during synthesis, the carbohydrate moiety was found to be made up of both -linked and -linked types and to constitute about 50% of the molecular mass. Digestion studies with neuraminidase and oligosaccharidase have indicated that the molecule is heavily sialated with most of the sialic acid located on the -linked sugars. The high carbohydrate content of gp340 appears to confer resistance to proteolysis; thus, V8 protease was only effective at concentrations above 1 mg/ml when three large fragments of mol. wt. 330K, 190K and 160K were generated. Removal of sialic acid before V8 protease digestion did not alter this pattern nor affect the antigenicity of the digestion fragments. Antigenicity of the intact molecule was likewise unaffected by removal of sialic acid nor were the -linked and -linked carbohydrate moieties essential for this property. The binding of virus-neutralizing human sera and monoclonal antibody by gp340 from which either -linked or -linked sugars had been removed seems to indicate that the sites on the molecule that generate the neutralizing antibodies are present in the protein component. The significance of these results is discussed in relation to the development of a subunit vaccine against EB virus.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-65-2-397
1984-02-01
2022-07-01
Loading full text...

Full text loading...

/deliver/fulltext/jgv/65/2/JV0650020397.html?itemId=/content/journal/jgv/10.1099/0022-1317-65-2-397&mimeType=html&fmt=ahah

References

  1. Brown W. R. A., Barclay A. N., Sunderland C. A., Williams A. F. 1981; Identification of a glycophorin-like molecule at the cell surface of rat thymocytes. Nature, London 289:456–460
    [Google Scholar]
  2. Cleveland D. W., Fischer S. G., Kirschner M. W., Laemmli U. K. 1977; Peptide mapping by limited proteolysis in sodium dodecyl sulphate and analysis by gel electrophoresis. Journal of Biological Chemisty 252:1102–1106
    [Google Scholar]
  3. Edson C. M., Thorley-Lawson D. A. 1981; Epstein-Barr virus membrane antigens: characterization, distribution, and strain differences. Journal of Virology 39:172–184
    [Google Scholar]
  4. Edson C. M., Thorley-Lawson D. A. 1983; Synthesis and processing of the three major envelope glycoproteins of Epstein-Barr virus. Journal of Virology 46:547–556
    [Google Scholar]
  5. Epstein M. A. 1976; Epstein-Barr virus - is it time to develop a vaccine program?. Journal of the National Cancer Institute 56:697–700
    [Google Scholar]
  6. Epstein M. A. 1979; Vaccine control of EB virus-associated tumors. In The Epstein-Barr Virus pp 440–448 Edited by Epstein M. A., Achong B. G. Berlin, Heidelberg & New York: Springer-Verlag;
    [Google Scholar]
  7. Epstein M. A., Morgan A. J. 1983; Clinical consequences of Epstein-Barr virus infection and possible control by an antiviral vaccine. Clinical and Experimental Immunology 53:257–271
    [Google Scholar]
  8. Franklin S. M., North J. R., Morgan A. J., Epstein M. A. 1981; Antigenic differences between the membrane antigen polypeptides determined by different EB virus isolates. Journal of General Virology 53:371–376
    [Google Scholar]
  9. Hoffman G., Lazarowitz S. G., Hayward S. D. 1980; Monoclonal antibody against a 250, 000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen. Proceedings of the National Academy of Sciences, U.S.A 77:2979–2983
    [Google Scholar]
  10. Johnson P. D. C., Spear G. 1983; O-linked oligosaccharides are acquired by herpes simplex virus glycoproteins in the Golgi apparatus. Cell 32:987–997
    [Google Scholar]
  11. Miller G., Shope T., Lisco H., Stitt D., Lipman M. 1972; Epstein-Barr virus: transformation, cytopathic changes, and viral antigens in squirrel monkey and marmoset leukocytes. Proceedings of the National Academy of Sciences, U.S.A. 69:383–387
    [Google Scholar]
  12. Morgan A. J., Epstein M. A., North J. R. 1983a; Comparative immunogenicity studies on Epstein-Barr (EB) virus membrane antigen (MA) with novel adjuvants in mice, rabbits and cotton-top tamarins. Journal of Medical Virology (in press)
    [Google Scholar]
  13. Morgan A. J., North J. R., Epstein M. A. 1983b; Purification and properties of the gp340 component of Epstein-Barr (EB) virus membrane antigen (MA) in an immunogenic form. Journal of General Virology 64:455–460
    [Google Scholar]
  14. North J. R., Morgan A. J., Epstein M. A. 1980; Observations on the EB virus envelope and virus-determined membrane antigen (MA) polypeptides. International Journal of Cancer 26:231–240
    [Google Scholar]
  15. North J. R., Morgan A. J., Thompson J. L., Epstein M. A. 1982a; Purified EB virus gp340 induces potent virusneutralizing antibodies when incorporated in liposomes. Proceedings of the National Academy of Sciences, U.S.A 79:7504–7508
    [Google Scholar]
  16. North J. R., Morgan A. J., Thompson J. L., Epstein M. A. 1982b; Quantification of an EB virus-associated membrane antigen (MA) component. Journal of Virological Methods 5:55–65
    [Google Scholar]
  17. Segrest J. P., Jackson R. L., Andrews E. P., Marchesi V. T. 1971; Human erythrocyte membrane glycoprotein: a re-evaluation of the molecular weight as determined by SDS polyacrylamide gel electrophoresis. Biochemical and Biophysical Research Communications 44:390–395
    [Google Scholar]
  18. Strnad B. C., Neubauer R. H., Rabin H., Mazur R. A. 1979; Correlation between Epstein-Barr virus membrane antigen and three large cell surface glycoproteins. Journal of Virology 32:885–894
    [Google Scholar]
  19. Thorley-Lawson D. A., Edson C. M. 1979; The polypeptides of the Epstein-Barr virus membrane antigen complex. Journal of Virology 32:458–467
    [Google Scholar]
  20. Thorley-Lawson D. A., Geilinger K. 1980; Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity. Proceedings of the National Academy ofSciences, U.S.A. 77:5307–5311
    [Google Scholar]
  21. Thorley-Lawson D. A., Poodry C. A. 1982; Identification and isolation of the main component (gp350–gp220) of Epstein-Barr virus responsible for generating neutralizing antibodies in vivo. Journal of Virology 43:730–736
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-65-2-397
Loading
/content/journal/jgv/10.1099/0022-1317-65-2-397
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error